n the four decades since Raymond Schofield postulated the concept of the stem cell niche as a specialized microenvironment dictating stem cell function in hematopoiesis 1 , specialized cellular niches have been well characterized in different stem cell models, with demonstrated roles in balancing stem cell quiescence and activity 2 . The niche is a special local site in the stromal microenvironment of stem cells that integrates signals reflecting tissue and organismal state 1 , and regulates stem cell fate commitment and epithelial cell plasticity during tissue homeostasis and regeneration 3 . In cancer, the niche can be shaped and subverted by tumour cells 4 . In this context, cancer can be viewed as an ecological entity that dynamically interacts with the microenvironment and forms specialized niches to support its expansion. As in normal stem cell niches, such malignant niches also dictate tumour cell hierarchy and regulate cancer stem cell activities 5 . During metastasis, stemlike properties of cancer cells are required to re-initiate tumour growth in distant tissues 6, 7 . Therefore, many parallels exist between the cancer stem cell niche and the metastatic niche at distant sites. However, the requirement of adapting to the distinct microenvironment of secondary organ sites means that the cellular composition and spatiotemporal functions of metastatic niches are often different to those of the primary tumour.
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The metastatic niche model posits that disseminated tumour cells (DTCs) seek out compatible niches to support their survival and growth, and that the metastatic niche co-evolves alongside disease progression 8, 9 . Steven Paget's 'seed and soil' hypothesis first indicated the necessity of a specific compatible 'soil' for the growth of metastases, forming the basis for the metastatic niche concept that is supported by recent experimental studies [8] [9] [10] . Metastatic niches can be formed either on arrival of DTCs in the recipient tissue 9 , or under the influence of secreted factors and/or exosomes released by the primary tumour prior to the seeding of DTCs (also termed the pre-metastatic niche) [10] [11] [12] . Many studies have reported the existence of pre-metastatic niches in different organs, such as lymph nodes (LNs), lung, liver, bone and, to a lesser extent, the brain 10 . Metastatic niche formation also occurs through occupancy of preexisting resident stem cell niches by DTCs. This phenomenon has been observed in bone metastasis 13 , but remains to be elucidated in other organs.
Identifying and characterizing metastatic niches is of paramount importance for the prevention and treatment of metastatic cancer, as colonization of a distant organ is considered to be the most rate-limiting step in the metastasis cascade 14 . Many aspects of the spatiotemporal formation of metastatic niches remain elusive. New studies use advanced confocal and multi-photon imaging technologies, combined with genetic tools, to accurately identify metastatic niche components and functions [15] [16] [17] [18] [19] . For example, vascular endothelial growth factor receptor 3 (VEGFR3) reporter mice were developed recently to allow real-time imaging of pre-metastatic niche formation in vivo 20 . Moreover, sophisticated, engineered animal models have been designed to deplete specific extracellular matrix (ECM) or stromal compartments 21 , or to induce loss-of-function genetic changes in specific cell types, including macrophages [22] [23] [24] , astrocytes 25, 26 or endothelial cells 27 . These models have provided tremendous functional knowledge of the metastatic niche in vivo.
In this Review, we focus on the specialized functions of metastatic niches, with particular emphasis on their role in regulating cellular plasticity and immune interactions. Metastatic cells require cancer stem cell features and high adaptability 6, 7 . Therefore, it is important that the niche preserves the cellular plasticity of DTCs to enable favourable immune interplay and immune editing of metastatic tumour cells. In particular, niche control of the epithelial-to-mesenchymal transition (EMT) and reverse mesenchymal-to-epithelial transition (MET) is a main modulator of cell plasticity. Throughout the Review, we focus on the dynamic relationships of the niche with the tumour cells that require intricate molecular communication, and discuss how disruption of such communication provides new therapeutic opportunities.
Common functions of the metastatic niches
The functions of the metastatic niche in supporting disease progression are multiple and can vary along the metastatic initiation process (Fig. 1) . DTCs undergo physical stress in circulation and thus, following extravasation, may require immediate niche support, for instance to provide physical anchorage, survival signals, immune surveillance protection and metabolic requirements. As DTCs recover from this stress, the niche also acts to preserve and protect the cancer stem cell phenotype and cellular plasticity from differentiation cues. The elongation of this initial phase can result in metastatic dormancy, which may persist for long periods of time depending on the interplay between the niche and the metastasisinitiating-cell (MIC) abilities of the DTCs. The niche can further foster metastatic outgrowth by providing supportive growth signals and facilitating cell plasticity and immune evasion. Despite the great variety of tumour-niche interaction in different cancer types and
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Metastatic seeding and anchorage.
A key function of the premetastatic and early metastatic niche is to facilitate the landing of cancer cells, providing anchorage while circumventing anoikis and apoptosis (Fig. 1a) . For example, in the perivascular niche, extravasated cancer cells remain attached to the external vessel walls, seeking physical support 16, 28 for recovery while remaining dormant 29 . Mesenchymal stem cells (MSCs), acting as pericytes surrounding the vasculature, aid this process 30 . The arriving DTCs further benefit from angiogenesis, lymphoangiogenesis 20 and vascular leakiness induced by primary tumour-secreted extracellular vesicles 31, 32 or cytokines such as VEGF, which promotes endothelial FAK/Eselectin-mediated permeability 33 . Vascular leakiness and tumour exosomes also have pro-inflammatory effects, increasing the expression of the chemoattractant S100A8/9 (refs 11, 32 ), which recruit circulating tumour cells (CTCs) to the pre-metastatic lung niche 34 .
Other chemoattractants, such as CXCL12 and CCL21, are highly expressed in common organs for metastasis (for example, LNs and lungs), and serve as homing receptors for CXCR4 + or CCR7 + breast cancer and melanoma cells 35 . The ECM is also important in metastatic seeding, as it provides compatible substrates for tumour cell anchorage through cell surface receptors, such as integrins and CD44 (refs 36, 37 + -reactive astrocytes expressing PD-L1. SPNS2 is an endothelial cell transporter that pumps sphingosine-1-phosphate (S1P) from metastatic tissues into circulation, preventing CD8 + T cell and NK cell recruitment. This chemo-protective function is promoted by increased ECM stiffness and stroma-dependent pro-survival signals, such as myeloid-derived S100A8/9, Notch signalling, or STAT1 and NF-κ B signalling. d, Proliferative licensing of metastasis is engaged by pro-survival signals and vascular sprouting, which awakens DTCs from the dormant state. Increased ECM stiffness triggers FAK/ERK proliferative signalling. NETs, which are networks of extracellular fibres, are primarily comprised of DNA from neutrophils and facilitate the invasive expansion of metastasis. In the bone marrow, RANKL, VCAM1 and Notch signalling in pre-osteoclasts stimulate osteoclastogenesis. This initiates a cycle of bone resorption and release of growth factors that feed back to cancer cells to promote osteolytic outgrowth for bone metastasis. CAFs, cancer-associated fibroblasts; EVs, extracellular vesicles; Grn, granulin; TANs, tumour-associated neutrophils; Rx, chemotherapy; Ob, osteoblast; Pre-oc, pre-osteoclasts.
SERIES | Review ARticle
https://doi.org/10.1038/s41556-018-0145-9
SERIES | Review ARticle
NaTure Cell Biology
Review ARticle | SERIES NaTure Cell Biology production to generate a pre-metastatic niche rich in fibronectin, favouring the ensuing metastasis 38 . This is similar to the fibroblast-secreted fibronectin in earlier reports of pre-metastatic niches 12 . Pancreatic tumour-derived exosomes stimulate transforming growth factor-β (TGF-β ) secretion in Kupffer liver cells, thereby inducing hepatic stellate cells to deposit fibronectin in the liver. In addition to anchoring MICs, fibronectin also favours the recruitment of bone marrow macrophages, contributing to liver pre-metastatic niche formation 24 . Macrophage-derived granulin activates hepatic stellate cells into myofibroblasts, which secrete periostin and favour collagen deposition to accommodate pancreatic cancer liver metastasis 39 . Both the composition and stiffness of the ECM are remodelled during pre-metastatic niche formation. For example, primary tumour cells secrete lysyl oxidase (LOX) into the circulation, which deposits in the lungs and cross-links collagen IV, creating a site that favours breast cancer metastasis 40 . Stromal cells also secrete ECM components and remodellers that promote lung metastatic colonization, such as matrix metalloproteinases (MMPs)-2 and 9 (refs 40, 41 ). ECM components and remodellers, such as PLOD2 and MMPs, are also produced by DTCs to generate their own ECM bed 42, 43 , providing immediate anchorage support for lung and LN metastasis. Alternatively, in bone metastasis, normal stem cell niches can be hijacked by arriving cancer cells to provide immediate attachment and shelter. For example, prostate cancer cells out-compete hematopoietic stem cells (HSCs) and occupy the endosteal osteoblastic niche 13 . Interestingly, neuroblastoma cells were recently shown to disseminate through peripheral nerves to innervated organs 44 , suggesting that MICs may use nerves as anchorage points to initiate metastatic colonization in distant organs.
Pro-survival-signalling support. During early seeding, the signals that prevent cell death are critical (Fig. 1b) . Integrin-FAK mechanotransduction through ECM engagement triggers pro-survival pathways, such as PI3K and MAPK signalling 45 , which are important for early survival at the metastatic site. The PI3K-AKT pathway is also activated in breast cancer cells by vascular cell adhesion molecule 1 (VCAM1)-mediated binding of recruited macrophages in lung metastasis 46 , and by stromal CXCL12 in the bone metastasis microenvironment 47 . MAPK-ERK signalling is induced in breast-MICs in the lungs by leukotrienes from recruited neutrophils 48 and by S100A8/9 from recruited granulocytic-myeloid-derived suppressor cells (MDSCs) 49 . The osteogenic bone niche induces the pro-survival mTOR pathway in micrometastases through heterotypic cadherin signalling between osteoblasts and DTCs (ref. 50 ). Tumour-derived Jagged1 (JAG1) also promotes secretion of interleukin-6 (IL-6) from osteoblasts to support bone metastatic cell survival and growth 51 . In the brain, L1CAM
+ metastatic tumour cells produce plasminogen activator (PA) inhibitory serpins to avoid apoptosis induced by soluble FasL from astrocytes 16 . On the other hand, reactive astrocytes engage pro-survival NF-κ B signalling in MICs, fostering survival and growth 26, 52 . Astrocyte-derived exosomes transfer miR-19a into brain MICs, which reduces PTEN levels and increases NF-κ B signalling and CCL2 secretion to promote IBA1 + myeloid cell recruitment for proliferation and reduced apoptosis of MICs (ref. 26 ). The metastatic niche also satisfies the energetic demands for DTC survival. For example, tumour exosomal miR-122 suppresses glucose metabolism in pre-metastatic niche cells to increase nutrient availability for DTCs (ref. 53 ). In liver metastasis, colorectal cancer cells take up creatine secreted from hepatocytes to obtain ATP and fulfil energetic requirements 54 . In the brain, MICs are able to use GABA released from neurons and convert it into NADH (ref. 55 ).
Protection from differentiation cues, immune surveillance and therapies. A critical function of the niche is to protect tumour cells from environmental differentiation cues and immune surveillance (Fig. 1c) , supporting their stemness and survival. Additionally, the metastatic niche can thwart therapeutic interventions by increasing ECM stiffness to limit the penetration of administered drugs 56, 57 , or by activating stroma-induced drug resistance pathways in MICs (ref. 58 ). During chemotherapy, myeloid cells recruited to metastatic sites, such as the lung, can promote chemoresistance and survival of MICs by secreting S100A8/9 (ref. 49 ). In brain metastasis, DTCs engage astrocyte gap-junction communication, which induces STAT1 and NF-κ B signalling in MICs and increases their chemoresistance to carboplatin 52 . In bone metastasis, cisplatin or paclitaxel chemotherapy induces JAG1 expression in osteoblasts, which engages Notch signalling in breast cancer cells and enhances chemoresistance of bone metastasis 51 .
Fostering proliferation and outgrowth. Metastatic niches often serve as the source of growth factors that stimulate metastatic lesion outgrowth (Fig. 1d) . ECM engagement of tumour cells through integrin-β 1 triggers FAK and ERK signalling, leading to rapid proliferation of micrometastases. This is further enhanced by increased ECM stiffness 59 and by the formation of cell protrusions that increase ECM interactions during lung metastasis 60, 61 . Impaired FAK/ERK signalling and soft ECM can both induce or maintain the dormant state of DTCs (ref. 62 ). In the bone microenvironment, expression of VCAM1 on indolent micrometastases recruits pre-osteoclasts and promotes osteoclast differentiation to increase bone degradation and the exit of micrometastasis from dormancy towards proliferation 63 . Dormancy can either be induced by metastatic niche signals or by the lack of activating signals 62, 64 . For example, in the bone marrow, high levels of TGF-β 2 induce p38-α /β MAPK and dormancy in DTCs (ref.
). In contrast, low TGF-β 2 levels in the lungs confer a more permissive niche allowing the formation of lung metastasis 65 . Another mechanism of dormancy exit is through vasculature sprouting and angiogenic-switch leading to proliferation of previously dormant cells 29 . Despite significant progress 64, 66 , how different organ-specific metastatic niches modulate dormancy requires further exploration.
Metastatic niche regulation of plasticity and stemness
Cellular plasticity is a core MIC characteristic that enables versatility and adaptation during metastatic colonization 6 , and is also critical for the epithelial homeostasis, reprogramming and tumorigenesis 67, 68 underlying the phenotypic interconversion between cancer stem cells (CSCs) and non-CSCs (refs 69, 70 ). This plasticity is modulated by environmental cues in both normal and malignant niches, driving tumour progression and metastasis 5, 71 . Recent studies have reported the differential needs for niche support in distant sites compared to the primary tumour site. For example, CD44 hi CD36
+ metastatic CSCs exhibit augmented lipid metabolism and consume high levels of environmental palmitic acid, promoting tumour-initiating ability at distant sites but not in the primary tumour 72 . Similarly, in colorectal cancer, ablation of the Lgr5 + CSC population inhibited the growth of established metastases but not of primary tumors 73 , indicating that the distant organ microenvironment specifically supports CSCs for metastatic growth.
Different components of the niche have been reported to preserve stemness in primary tumours, which can be recapitulated in metastasis (Fig. 2) . For instance, in the primary tumour niche, cancer-associated fibroblasts (CAFs) secrete multiple factors to induce stem-cell-related pathways, including Wnt and Notch signalling 5 . At the metastatic niche, microenvironmental TGF-β from tumour or stromal cells induces CAFs to secrete ECM niche components, such as periostin and tenascin-C, to maintain the stemness of metastatic cells 21, 74 . Periostin activates Wnt signalling 21 and tenascin-C induces Notch and Lgr5 signalling 74 to drive stem cell properties in breast cancer MICs. Tenascin-C is also secreted by MICs as an autonomous mechanism to preserve their stemness 74 . In addition, TGF-β Review ARticle | SERIES https://doi.org/10.1038/s41556-018-0145-9
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NaTure Cell Biology -activated fibroblasts secrete IL-11 to induce STAT3, an important transcription factor that promotes stemness of colorectal CSCs and metastasis initiation in the liver and lungs 75, 76 . Direct interactions between tumour cells and MSCs have been shown to induce stem cell signaling 77 , in part through increasing miR-199a expression in breast cancer cells 78 . This could also occur in the metastatic niche, as MSCs are found in multiple distant locations 79, 80 . miR-199a is also important for normal and breast cancer stem cell plasticity, protecting CSCs from differentiation and senescence elicited by macrophage-secreted IFN-α and promoting tumour initiation, both at primary and metastatic sites 81 . The same miRNA also promotes melanoma metastatic colonization by favouring the recruitment of endothelial cells 82 . Thus, miR-199a may facilitate metastasis by modulating the interaction with different components of the metastatic niche (Fig. 2) . At the perivascular niche, endothelial sprouts release periostin, tenascin-C and TGF-β in breast cancer micrometastasis to maintain stemness through Wnt and Notch signalling 29 . Notch signalling also promotes stemness in brain metastasis by the direct interaction of breast cancer cells with JAG1-positive astrocytes 83 . In lung metastasis, breast cancer cells secrete Coco to inhibit BMP signalling and prevent Wnt inhibition, which preserves the cellular plasticity needed to exit from dormancy 84 . Importantly, direct contact of atypical tetraspanin TM4SF1 in dormant cancer cells with collagen I at the metastatic niche mediates non-canonical DDR1-STAT3 signalling in cancer cells, leading to increased SOX2 and NANOG expression, activation of cancer stem cell properties and formation of metastasis at multiple organ sites 85 ( Fig. 2) . On the other hand, autocrine inhibition of Wnt signalling in DTCs is important to escape immune surveillance during metastatic latency; however, these cells still display a CSC phenotype and express high levels of SOX2/SOX9, suggesting the maintenance of stemness independently of Wnt (ref. 86 ). These findings underscore a critical role of the metastatic niche in regulating the stem cell properties and plasticity to favour metastatic colonization, particularly through the Wnt-Notch and STAT3-SOX2-NANOG signalling pathways (Fig. 2) .
Metastatic niche modulation of the eMT/MeT states
EMT is a form of cellular transdifferentiation that requires high levels of cellular plasticity, and has been linked to the stem cell gene programs 67, 87 . While EMT is known to promote invasive behaviour and cancer stem cell properties, recent evidence also demonstrated the requirement of the reverse process, MET, for successful metastatic colonization in distant organs [88] [89] [90] . Indeed, extreme mesenchymal states are considered less metastatic and less plastic 89, 91, 92 , losing adaptability to hostile environments. This extreme mesenchymal differentiation is a plausible explanation for recent reports suggesting that EMT is not required for metastasis 93, 94 . In contrast, metastatic cancer cells in partial EMT or MET states are highly plastic, with enhanced metastasis-initiation abilities 6, 61, 95 . Intermediate EMT states with metastatic ability and plasticity have been recently identified in skin and breast tumours in vivo, in a study that also showed how the primary tumour niche regulates different EMT transition states 96 . Thus, metastatic niches may also be important in mediating the interconversion of epithelial and mesenchymal state plasticity (Fig. 2) .
Metastatic niche ECM components and stiffness can induce EMT at the metastatic site, prompting stem cell properties and ). In turn, EMT cells secrete ECM proteins to help construct a permissive niche for themselves 100 . However, in the later phase of metastasis development, TGF-β and EMT need to be reduced to favour proliferation and metastatic outgrowth 95, 101 . Indeed, DTCs arriving at new organs mostly display EMT-like features with stem cell gene signatures but maintain a quiescent state 102 . However, to progress to macrometastasis, they change to a more epithelial phenotype, downregulate stem cell gene programs related to quiescence, and express proliferative genes related to stemness, such as Myc (ref. 102 ). Recent studies delve into how the metastatic niche modulates EMT reversion (Fig. 2) . For example, CD11b + Gr1 + bone marrow myeloid progenitor cells recruited in the lungs secrete versican to induce MET and proliferation in the arriving EMT-like cells 103 . Similarly, pulmonary granulocytic myeloid-derived suppressor cells (MDSCs) induce MET in the arriving EMT-like cells to enhance metastatic growth 104 , with EMT-like cells promoting the recruitment of immature myeloid cells in the lung even before their arrival 105 . Arriving EMT-like DTCs can also secrete thrombospondin-2 (THSB2) to activate lung fibroblasts, which in turn promote MET and proliferation of DTCs by activating BMP-SMAD1/5 signalling during metastatic colonization 106 . This MET process allows tumour cells to gain plasticity without losing stemness, supporting the notion that tumour cells in the transitional EMT/MET state are maximally plastic and potent in forming metastasis 6, 96, 107 .
Tumour-immune cell interplay at metastatic sites
Tumour cells develop strategies to modulate and recruit different immune cells with immunosuppressive effects. Bone-marrowderived myeloid cells are commonly recruited to the metastatic niche to suppress anti-metastatic immune responses in different organs (Fig. 1c) . In particular, macrophages and neutrophils have been shown to suppress T cell infiltration and activation, thereby promoting metastasis 108, 109 . In breast cancer metastasis, Gr1
+ inflammatory monocytes are recruited to the lung by CCL2 released from DTCs, and then differentiate into macrophages to support metastatic seeding 23 . Surgical procedures can generate a systemic effect that recruits macrophages, triggering outgrowths of distant metastasis 110 . In fact, tumour-secreted Dockkopf-related protein 1 (DKK1) inhibits macrophage and neutrophil recruitment and thus prevents lung metastasis 111 . Conversely, in the bone DKK1 inhibits Wnt signalling in osteoblasts and prevents osteoprotegerinblockade of osteoclast differentiation, thereby promoting osteoclastogenesis and metastasis 111 . This mechanism illustrates how the same molecule may have a differential role in different organs by signalling through different cell types within the niche. Neutrophils also have important effects in the niche. For example, endothelial cells with persistently activated Notch-signalling induce VCAM1 expression, which stimulates neutrophil infiltration to facilitate melanoma lung metastasis 112 . Neutrophils extrude DNA-containing extracellular traps (NETs) during infectious disease 113 , and these NETs have been reported to increase breast cancer metastasis initiation in the lung 114 . Organ-specific myeloid cells can stimulate brain metastasis growth. This is the case for astrocyte-derived exosomes, which induce recruitment of IBA1 + myeloid cells to promote growth of brain metastatic tumors 26 . In addition, brain pSTAT3 + reactive astrocytes express macrophage-migration inhibitory factor (MIF) to induce migration and recruitment of organ-resident CD74 + microglia and macrophages 25 . Moreover, pSTAT3 + reactive astrocytes protect breast, lung and melanoma MICs from the immune system by forming a physical barrier and expressing programmed cell death-ligand 1 (PD-L1) to suppress infiltrating CD8 + T cell activity 25 . MDSCs, which are immature myeloid cells, are important immune-suppressors of metastasis in different organs, including the lung, liver, bone and brain 109, 115, 116 . For instance, MDSC-secreted osteopontin (OPN) reduces CD8 + T cell proliferation, thus exerting an immunosuppressive function at the lung metastatic niche 117 . Oncogenic mTOR signalling in cancer cells enhances MDSC recruitment to the lungs through granulocyte-colony stimulating factor (G-CSF), which suppresses T cell infiltration and increases metastasis initiation 118 . Similarly, CXCR2 signalling in neutrophil and MDSCs prevents CD3 + T cell infiltration and tumour cell killing in the liver metastatic niche 119 . Regulatory T cells (Tregs) have strong immunosuppressive effects on T cells and natural killer (NK) cells 120 . However, their role in distant sites is less known. Tregs isolated from metastatic lymph nodes have been shown to inhibit the proliferation and activation of CD4 + and CD8 + T cells in vitro 121 .
The balance of Tregs versus CD8
+ T cells present in the lung parenchyma is critical for lung metastatic colonization, as elegantly illustrated in a genetic screen study using knockout mice to identify the host tissue factor Spns2 as a regulator of Treg recruitment as well as NK and T cell accumulation that modulates anti-metastatic immunity 27 . Together, these studies support the hypothesis that immunesuppressive cells are recruited into the metastatic niche to create a metastasis-promoting microenvironment.
Metastatic niche immunoediting
Cancer immunoediting is the process that shapes tumour immunity during primary tumour formation, and consists of three phases: elimination, equilibrium and escape 122 . Given that the immune context of the primary tumour site can be recapitulated in the metastatic site to a certain extent 123 , DTCs could potentially have been immune-edited to evade detection by the immune system even when they are still at the primary site. Nevertheless, the hostile immune environment at the metastatic site has been evidenced in multiple studies, and represents a major obstacle for metastatic colonization [124] [125] [126] [127] [128] , suggesting that DTCs must undergo secondary immune-editing at distant organs, at least for a period of time until they are able to establish a more permissive niche. Despite the lack of direct evidence of metastatic immunoediting, in the context of adoptive immunotherapy, cycling indolent (but not quiescent) metastatic cells were immune-edited and finally escaped to form macrometastasis 129 . Although not well characterized, different degrees of secondary immunoediting likely co-evolve with the maturation of the metastatic niche. Cancer immunoediting is a long process that can last for years, particularly at the equilibrium phase 130 . Therefore, earlydisseminated tumour cells are likely to leave the primary tumour before completing the immune-editing process, and to require further immune editing once established at the metastatic niche [131] [132] [133] . Indeed, a secondary round of immune editing could explain metastatic dormancy as a prolonged equilibrium phase. This type of dormancy has long been reported as 'active suppression' by the immune system that counterbalances the proliferation rate of DTCs, thereby resulting in dynamic but steady, non-clinically detectable micrometastases 134, 135 . Different organs have distinct resident and recruited immune cells that represent different challenges for arriving DTCs to establish metastasis [136] [137] [138] . Consequently, heterogeneous immune microenvironments determine different metastatic outcomes in different organs within the same individual, depending on the immune context of each organ seeded 138 . Therefore, immune interaction with cancer cells continues beyond the primary tumour, and immune editing likely determines the pace of metastatic colonization.
Therapeutic opportunities targeting the metastatic niche
The necessity of a metastatic niche implies the opportunity to therapeutically block its molecular and cellular interactions with DTCs to prevent or reduce metastasis. In the brain metastatic niche, astrocytes were observed to interact with DTCs through gap junctions to promote their survival 52 . Using the FDA approved gap junction Review ARticle | SERIES https://doi.org/10.1038/s41556-018-0145-9
Review ARticle | SERIES SERIES | Review ARticle NaTure Cell Biology inhibitors tonabersat and meclofenamate to target brain metastasis in a pre-clinical setting showed promising results, and has been followed by clinical trials using the same strategy to treat brain metastasis (ClinicalTrials.gov; NCT02429570) 52 . In a separate study, use of nutraceutical Legasil (Silibinin) to inhibit STAT3 activity successfully reduced the immunosuppressive effect of reactive astrocytes and suppressed brain metastasis 25 . Osteoclast-targeting agents, bisphosphonates and denosumab (RANKL blocking antibody) have been clinically approved for the treatment of bone metastasis 139 . A therapeutic antibody against JAG1 has been shown to block tumour-stromal interactions and displayed a strong synergy with chemotherapy in reducing bone metastasis and chemoresistance 51 . A monoamine oxidase A inhibitor has also been used to block Shhsecretion from cancer cells, thus preventing osteoblast stimulation and release of RANKL and IL-6 in prostate cancer metastasis 140 . These studies demonstrate that targeting the survival and chemoprotective function of the niche represents promising strategies for therapeutic invention of metastasis (Fig. 3) .
A major problem in the clinical management of cancer is metastatic dormancy, as it presents a risk of relapse and undermines the therapeutic benefit of treatment. In addition to maintaining residual cancer cells at a dormant state, two alternative strategies have been proposed to target dormancy 66 . The first is to disrupt the anchorage function of the niche to enhance mobilization and vulnerability of tumour cells. For example, blockade of SDF-1 and E-selectin dislodges dormant breast cancer cells from perisinusoidal vascular regions and mobilizes dormant micrometastasis out of the bone marrow to prevent metastatic colonization 28 . The anchorage function of the ECM and blood vessels could also be targeted with anti-LOX (ref. 141 ), anti-MMPs (ref.
142
) and anti-VEGF (ref. 143 ) (Fig. 3) . Alternatively, blocking niche-protection and survival functions, such as niche-derived factors that induce chemoresistance to DTCs, represents another dormancy-targeting regimen. Taken together, these strategies will be critical in eliminating any minimal residual disease and work towards a complete cure for the patient.
The pro-metastatic immune cells forming the metastatic niche also represent an excellent target for therapeutic intervention (Fig. 3) . CCL2/CCR2-mediated macrophage recruitment in lung metastasis 23 could be blocked with CCL2 inhibitors that have been shown to have therapeutic effects in primary tumours 144 . Endothelial Notch1 and VCAM1-blockade prevents ovarian lung metastasis by preventing neutrophil infiltration 112 . In pre-clinical models, DNase-I-coated nanoparticles have been shown to be a potential therapeutic inhibitor of metastasis through digestion of DNA in NETs (ref. 114 ). The inhibition of CXCR2 on MDSCs allows T cell infiltration in pancreatic liver metastasis, which enhances the efficiency of anti-PD1 immunotherapy 119 . Overall, immunotherapy approaches have achieved outstanding results in certain metastatic cancer types and hold great promise in oncology 145 . However, recent long-term follow-up studies have shown acquired resistance to the initial treatment in a quarter of melanoma . Therefore, it is critical to study the immune metastatic niche formation and its dynamic immune-editing to understand the acquired immunoresistance of MICs.
Identification of new niche functions and different types of metastatic niches will continue to increase the range of therapeutic options. The emergence of neural niches may allow use of a multitude of available neurotransmitter modulators, such as vigabatrin, to block GABA transaminase (ABAT) and to avoid GABA catabolism, which has been experimentally shown to be important in brain metastasis 55 . Another putative metastatic niche is the bacterial niche, which could also be classified as 'xeno-niche' as it is formed by different species. For example, Fusobacterium and its associated microbiome are found in primary and metastatic locations, and support cancer cell proliferation and growth by unknown mechanisms 147 . Xeno-niches represent an ideal therapeutic target by using antibiotics to directly kill the specific bacteria and abrogate their supportive function, as shown in a recent study using metronidazole 147 . These emerging niches will offer more opportunities to specifically target metastasis depending on location, function and timing.
Concluding remarks
In this Review, we describe the metastatic niche functions that provide a permissive environment for eventual outgrowth of DTCs in distant organ sites. We classify these functions into four main categories: anchorage, survival, protection and proliferation (Figs. 1, 3) . Furthermore, two central themes are shared when considering the interaction between MICs and metastatic niches: the maintenance of cancer stemness and plasticity, and the metastasis-favouring immune interplay and editing. This is not meant to be an exhaustive list of niche functions, as on-going and future research will undoubtedly reveal further complexities. Furthermore, different organs may have different types of niches that facilitate the metastatic process, as evidenced by the organotropism of different cancer types 139 . Proposing common functions among different niches and in different organs is intended to provide a conceptual framework that may prove useful when considering therapeutic strategies to target metastasis. It is also important to consider that metastatic niches are constantly evolving, and thus some functions are more important at early stages and others at later stages. Therefore, future pre-clinical studies should focus on experimentally testing the critical therapeutic windows to shut down common niche functions, according to the timeline of metastatic colonization steps. For these studies, the application of advanced imaging and single cell -omics techniques will help decipher the spatiotemporal dynamics of tumour-niche interactions. Development of niche reporters or niche-specific imaging probes will be very informative regarding the dynamics of metastatic niches, especially when utilizing clinically applicable technologies such as positron emission tomography (PET) and nuclear magnetic resonance (NMR). Engineering threedimensional model systems in vitro and using niche-mimicking biomaterials that regulate functions following implantation in vivo 148 , will help to deconstruct the metastatic niche. Combinatorial gene function analysis within tissues at a temporal and cellular resolution can reveal the roles of multiple niche stromal populations, as exemplified by the recently reported dual-IGF mosaic mice 149 . It is worth noting that many metastasis studies use experimental metastasis models in which tumours cells are introduced directly into circulation. In such models, the dynamics of metastatic niche development might be substantially different from models of spontaneous metastasis, which often take much longer to develop. Careful comparison of the metastasis niches in these different models might help provide important insights in clinical settings.
Metastasis research has been limited by the difficulty of obtaining clinical samples. This is even more challenging when studying the pre-metastatic niche, as pre-metastatic tissues are difficult to detect and not normally resected. However, experimental models and advanced technologies clearly show the importance of the niche in metastatic disease. We expect that future research into metastatic niche functions will continue to provide conceptual frameworks to develop new therapies for containing or eliminating metastatic disease. In particular, a better understanding of how the niche regulates cellular plasticity and immune evasion holds great potential for therapeutic intervention of metastasis, as both functions are required across all metastatic stages and organs.
